Nov 29, 2022
Mar 31, 2024
Dr. Sanjay Juneja is a triple board certified Hematologist & Medical Oncologist serving as Chief of Oncology Service at Baton Rouge General Hospital, and a social & news media personality known as 'TheOncDoc' with over half a million followers. He is an active participant for the White House Healthcare Leaders in Social Media Roundtable and national speaker. Dr. Juneja is the host of an innovative podcast called 'Target: Cancer' with distinguished academicians and celebrities around the country, and been featured in several articles including The Washington Post and guested on dozens of acclaimed podcasts and regional news channels (PBS, CBS, NBC, NPR). He is a Business Report's 40 under 40 recipient from his hometown of Baton Rouge, where he partners with the LA Department of Health and Mayor's office to optimize healthcare access and outreach. Dr. Juneja currently practices in his beloved hometown of Baton Rouge Louisiana with his wife Dr. Lauren and their three wild boys.
Associate Director, Center for Integrated Diagnostics
Assistant Professor, Harvard Medical School
Assistant Pathologist, Massachusetts General Hospital
Lauren Ritterhouse, MD, PhD, specializes in diagnostic molecular genetic pathology with expertise in biomarkers for personalized medicine in cancer. She is a member of the Center for Integrated Diagnostics (CID) at Massachusetts General Hospital.
Dr. Ritterhouse joined the Massachusetts General Hospital Department of Pathology and Center for Integrated Diagnostics as a staff pathologist in 2019. Prior to this, she was the Co-Director of the clinical genomics and molecular diagnostic laboratories at the University of Chicago. She received her MD, PhD from the University of Oklahoma where she studied the pathogenic roles of aberrant cytokine production in autoimmunity. She completed a Molecular Genetic Pathology Fellowship at Harvard Medical School and Anatomic Pathology Residency at Brigham and Women’s Hospital in Boston, MA. She is particularly interested in the translation of emerging molecular biomarkers into the clinical laboratory, including those evaluating response to immunotherapy, solid tumor mutational signature profiling, circulating tumor DNA, as well as hematologic malignancies.